Aurora Kinases As Therapeutic Targets in Head and Neck Cancer

Overview

Journal Cancer J

Specialty Oncology

Date 2022 Sep 27

PMID 36165728

Authors

Theodore T Nguyen

Flaviane N Silva

Erica A Golemis

Affiliations

Soon will be listed here.

Abstract

The Aurora kinases (AURKA and AURKB) have attracted attention as therapeutic targets in head and neck squamous cell carcinomas. Aurora kinases were first defined as regulators of mitosis that localization to the centrosome (AURKA) and centromere (AURKB), governing formation of the mitotic spindle, chromatin condensation, activation of the core mitotic kinase CDK1, alignment of chromosomes at metaphase, and other processes. Subsequently, additional roles for Aurora kinases have been defined in other phases of cell cycle, including regulation of ciliary disassembly and DNA replication. In cancer, elevated expression and activity of Aurora kinases result in enhanced or neomorphic locations and functions that promote aggressive disease, including promotion of MYC expression, oncogenic signaling, stem cell identity, epithelial-mesenchymal transition, and drug resistance. Numerous Aurora-targeted inhibitors have been developed and are being assessed in preclinical and clinical trials, with the goal of improving head and neck squamous cell carcinoma treatment.

Citing Articles

Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma.

Korns J, Wicker C, Lehn M, Shyamsunder S, Thompson S, Lester C Cancer Lett. 2024; 606:217320.

PMID: 39489210 PMC: 11583984. DOI: 10.1016/j.canlet.2024.217320.

The two sides of chromosomal instability: drivers and brakes in cancer.

Hosea R, Hillary S, Naqvi S, Wu S, Kasim V Signal Transduct Target Ther. 2024; 9(1):75.

PMID: 38553459 PMC: 10980778. DOI: 10.1038/s41392-024-01767-7.

Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.

Candido M, Medeiros M, Veronez L, Bastos D, Oliveira K, Pezuk J Pharmaceutics. 2023; 15(2).

PMID: 36839989 PMC: 9966033. DOI: 10.3390/pharmaceutics15020664.

References

Wang X, Sinn A, Pollok K, Sandusky G, Zhang S, Chen L . Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol. 2010; 150(3):313-25. DOI: 10.1111/j.1365-2141.2010.08248.x. View

Aguirre-Portoles C, Bird A, Hyman A, Canamero M, Perez de Castro I, Malumbres M . Tpx2 controls spindle integrity, genome stability, and tumor development. Cancer Res. 2012; 72(6):1518-28. DOI: 10.1158/0008-5472.CAN-11-1971. View

Plotnikova O, Pugacheva E, Dunbrack R, Golemis E . Rapid calcium-dependent activation of Aurora-A kinase. Nat Commun. 2010; 1:64. PMC: 2963827. DOI: 10.1038/ncomms1061. View

Yang J, Zappacosta F, Annan R, Nurse K, Tummino P, Copeland R . The catalytic role of INCENP in Aurora B activation and the kinetic mechanism of Aurora B/INCENP. Biochem J. 2008; 417(1):355-60. DOI: 10.1042/BJ20081365. View

Wu J, Yang L, Shan Y, Cai C, Wang S, Zhang H . AURKA promotes cell migration and invasion of head and neck squamous cell carcinoma through regulation of the AURKA/Akt/FAK signaling pathway. Oncol Lett. 2016; 11(3):1889-1894. PMC: 4774610. DOI: 10.3892/ol.2016.4110. View

Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N . Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2008; 15(1):67-78. DOI: 10.1016/j.ccr.2008.12.005. View

Sootome H, Miura A, Masuko N, Suzuki T, Uto Y, Hirai H . Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes and : Preclinical Studies as Guidance for Clinical Development and Trial Design. Mol Cancer Ther. 2020; 19(10):1981-1991. DOI: 10.1158/1535-7163.MCT-20-0036. View

Khaddour K, Jonna S, Deneka A, Patel J, Abazeed M, Golemis E . Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers (Basel). 2021; 13(13). PMC: 8267708. DOI: 10.3390/cancers13133164. View

Tatsuka M, Sato S, Kanda A, Miki T, Kamata N, Kitajima S . Oncogenic role of nuclear accumulated Aurora-A. Mol Carcinog. 2009; 48(9):810-20. DOI: 10.1002/mc.20525. View

10.

Nikonova A, Astsaturov I, Serebriiskii I, Dunbrack Jr R, Golemis E . Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci. 2012; 70(4):661-87. PMC: 3607959. DOI: 10.1007/s00018-012-1073-7. View

11.

Nguyen H, Chinnappan D, Urano T, Ravid K . Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property. Mol Cell Biol. 2005; 25(12):4977-92. PMC: 1140599. DOI: 10.1128/MCB.25.12.4977-4992.2005. View

12.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

13.

Asteriti I, Rensen W, Lindon C, Lavia P, Guarguaglini G . The Aurora-A/TPX2 complex: a novel oncogenic holoenzyme?. Biochim Biophys Acta. 2010; 1806(2):230-9. DOI: 10.1016/j.bbcan.2010.08.001. View

14.

Semrad T, Kim E, Gong I, Li T, Christensen S, Arora M . Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2021; 88(2):335-341. PMC: 8259450. DOI: 10.1007/s00280-021-04293-3. View

15.

Manfredi M, Ecsedy J, Chakravarty A, Silverman L, Zhang M, Hoar K . Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res. 2011; 17(24):7614-24. DOI: 10.1158/1078-0432.CCR-11-1536. View

16.

Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F . Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. 2004; 64(9):3103-11. DOI: 10.1158/0008-5472.can-03-3968. View

17.

Shigeishi H, Fujimoto S, Hiraoka M, Ono S, Taki M, Ohta K . Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas. Int J Oncol. 2009; 34(6):1565-71. DOI: 10.3892/ijo_00000286. View

18.

Grandis J, Tweardy D . Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993; 53(15):3579-84. View

19.

. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517(7536):576-82. PMC: 4311405. DOI: 10.1038/nature14129. View

20.

Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, ODASHIMA S . Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst. 1999; 91(13):1160-2. DOI: 10.1093/jnci/91.13.1160. View